8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
GILEAD SCIENCES, INC. (GILD)

Gilead ($GILD) filed a Form 8‑K on Feb 10, 2026: Exhibit 99.1 = press release (Feb 10, 2026) and Exhibit…

Filed with the SEC on · Summarized by InvestorsBot

Gilead ($GILD) filed a Form 8‑K on Feb 10, 2026: Exhibit 99.1 = press release (Feb 10, 2026) and Exhibit 104 = Inline XBRL cover page. Filing signed by CFO Andrew D. Dickinson. Investors should read the press release for material updates. 📄✍️ #SECfiling #Biotech

Item 9.01 shows only a press release (Ex.99.1) and XBRL cover page (Ex.104)—no additional financial statements or agreements disclosed in this 8‑K. Review the attached press release for any operational/financial impact. 🔎 $GILD #Investors #Gilead

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from GILEAD SCIENCES, INC.

Gilead filed exhibits re: an acquisition — Agreement & Plan of Merger (dated Feb 22, 2026) among Gilead,…

8-K · February 23, 2026

Feb 23, 2026: $GILD and $ACLX announced they signed a Merger Agreement and the FDA accepted the BLA for…

8-K · February 23, 2026

BREAKING: $GILD strikes deal to buy Arcellx — tender offer $115/.share + 1 CVR (up to $5 more if anito‑cel…

8-K · February 23, 2026

Gilead ($GILD) announced Q4 & FY 2025 results on Feb 10, 2026; press release is filed as Exhibit 99.1 to…

8-K · February 10, 2026